1 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)Bites and Stings, Chemically-Induced Disorders, Neoplasms by Site, Thoracic Neoplasms, injury, lung disorder, lung neoplasm, neoplasm, poisoning, respiratory system disorder, respiratory tract neoplasmActive, not recruitingPhase 12026-09-09NCT05361395